Gilead Sciences, Inc. (0QYQ.IL)
| Previous Close | 68.39 |
| Open | 68.33 |
| Bid | 63.91 x N/A |
| Ask | 70.62 x N/A |
| Day's Range | 67.15 - 68.33 |
| 52 Week Range | 62.14 - 87.53 |
| Volume | |
| Avg. Volume | 33,573 |
| Market Cap | 83.713B |
| Beta (5Y Monthly) | 0.35 |
| PE Ratio (TTM) | 15.44 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.00 (3.81%) |
| Ex-Dividend Date | Sept 14, 2023 |
| 1y Target Est | N/A |
- Simply Wall St.
Should You Be Concerned About Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- GuruFocus.com
Insider Sale: Chief Medical Officer Merdad Parsey Sells Shares of Gilead Sciences Inc (GILD)
Following this sale, the insider now owns 96,380 shares of Gilead Sciences Inc. Gilead Sciences Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. The company's portfolio includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
- Insider Monkey
Should You Hold Gilead Sciences (GILD)?
Parnassus Investments, an investment management company, released the “Parnassus Value Equity Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. In the first quarter, the Fund (Investor Shares) appreciated 10.17% outperforming the Russell 1000 Value Index’s 8.99%. Stock selection in the Information Technology and Communication Services sectors was the […]
